Spectral AI partners with ABWM Foundation to promote Wound Healing Awareness Month, highlighting its DeepView System for burn wound evaluation.
Quiver AI Summary
Spectral AI, Inc., a medical diagnostics company specializing in AI for wound care, is collaborating with the American Board of Wound Management Foundation to celebrate the 10th Annual Wound Healing Awareness Month this June. CEO Vincent Capone emphasized the importance of timely diagnoses and tailored treatments for patients with complex burn wounds. The company recently received FDA De Novo Classification for its DeepView System, a non-invasive device that uses multispectral imaging and AI to assess burn wound healing potential, helping clinicians make informed treatment decisions quickly. Spectral AI aims to enhance patient outcomes and was recognized in TIME’s 2025 list of World’s Top HealthTech companies.
Potential Positives
- Spectral AI's DeepView System received FDA De Novo Classification, indicating it meets safety and effectiveness standards for burn wound assessment.
- The partnership with the ABWM Foundation highlights Spectral AI's commitment to advancing wound care and supporting certified specialists.
- The DeepView System promises to improve patient outcomes and reduce healthcare costs by providing timely and accurate diagnostics for burn wounds.
- Spectral AI was named to TIME’s list of World’s Top HealthTech companies in 2025, enhancing its reputation in the healthcare technology industry.
Potential Negatives
- The mention of "forward-looking statements" highlights potential risks and uncertainties regarding the company's future performance, which may concern investors.
- The press release does not provide financial details or projections following the FDA classification of the DeepView System, leaving stakeholders without key information on expected financial impact.
- The emphasis on the DeepView System's ability to improve patient outcomes raises expectations that may not be met, creating potential reputational risks if the product does not perform as anticipated.
FAQ
What is the DeepView System by Spectral AI?
The DeepView System is a non-invasive medical device that assesses burn wound healing potential using AI and multispectral imaging.
Who is celebrating Wound Healing Awareness Month?
Spectral AI is joining the American Board of Wound Management (ABWM) Foundation to celebrate the 10th Annual Wound Healing Awareness Month.
What does the DeepView System provide to clinicians?
The system offers immediate, data-driven assessments of burn wounds to aid in informed treatment decisions.
Why is Wound Healing Awareness Month important?
This month raises awareness for patients with burn wounds, highlighting the need for timely and accurate diagnoses and treatment options.
When did the DeepView System receive FDA approval?
The DeepView System was granted FDA De Novo Classification in May 2026, enabling its use in clinical settings.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDAI Revenue
$MDAI had revenues of $4M in Q1 2026. This is a decrease of -40.5% from the same period in the prior year.
You can track MDAI financials on Quiver Quantitative's MDAI stock page.
You can access data on MDAI stock through the Quiver Quantitative API.
$MDAI Hedge Fund Activity
We have seen 9 institutional investors add shares of $MDAI stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HUDSON BAY CAPITAL MANAGEMENT LP removed 1,526,716 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,244,272
- VANGUARD GROUP INC added 228,777 shares (+37.3%) to their portfolio in Q4 2025, for an estimated $324,863
- JANE STREET GROUP, LLC added 168,409 shares (+320.2%) to their portfolio in Q1 2026, for an estimated $247,561
- MARSHALL WACE, LLP removed 145,482 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $206,584
- DNB ASSET MANAGEMENT AS removed 136,473 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $200,615
- GEODE CAPITAL MANAGEMENT, LLC added 84,649 shares (+39.1%) to their portfolio in Q1 2026, for an estimated $124,434
- VIRTU FINANCIAL LLC removed 52,547 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $77,244
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MDAI Analyst Ratings
Wall Street analysts have issued reports on $MDAI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 03/25/2026
To track analyst ratings and price targets for $MDAI, check out Quiver Quantitative's $MDAI forecast page.
Full Release
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, is joining the American Board of Wound Management (ABWM) Foundation in celebrating the 10 th Annual Wound Healing Awareness Month.
In this milestone year, during the month of June the ABWM Foundation will continue its mission of raising awareness, empowering certified wound care specialists, and transforming lives.
“Wound Healing Awareness Month is an important reminder that patients living with painful, sometimes complex burn wounds require a timely, accurate diagnosis and a tailored treatment pathway,” said Vincent Capone, Chief Executive Officer of Spectral AI. “By helping clinicians rapidly and objectively evaluate the healing potential of acute burn wounds, our AI-driven DeepView ® System for burn indication - which was granted FDA De Novo Classification in May 2026 - is designed to support more informed treatment decisions that can lead to improved outcomes and quality of life for patients and their families.
“We are especially proud to celebrate the dedicated and talented certified wound care specialists who every day deliver exceptional expertise, compassion, and care to patients across the country. They play a vital role in advancing healing and improving lives.”
About the DeepView System
Spectral AI's DeepView System, which was granted FDA De Novo Classification in May 2026, is a non-invasive, predictive medical device which combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within the burn wounds. The DeepView System provides clinicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.
About the American Board of Wound Management
The ABWM Foundation is a 501(c)(3) not-for-profit foundation. It supports the work of the American Board of Wound Management (
ABWM
) for the advancement of wound care, the promotion of certification for providers of chronic and acute wounds, and the benefit of the public by developing and providing quality education and conducting sound research to support and promote wound care. Learn more at
https://abwmfoundation.org/about/
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit
www.spectral-ai.com
.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
|
Investors:
The Equity Group |
|
|
Devin Sullivan
Managing Director [email protected] |
Conor Rodriguez
Associate [email protected] |